Citations

Clear

4610 citation(s) found for "Lu, Brian".

LC-MS/MS Quantification of Zn-α2 Glycoprotein: A Potential Serum Biomarker for Prostate Cancer
Bondar, Olga P., Barnidge, David R. , Klee, Eric W. , Davis, Brian J. , Klee, George G., Davis, Brian J

Mayo Clinic

Clinical Chemistry | February 23, 2007 | Volume: 53 | Issue: 4 | Pages: 673-678

10.1373/clinchem.2006.079681 | PMID 17317883 Get It

AbstractBackground: Zn-α2 glycoprotein (ZAG) is a relatively abundant glycoprotein that has potential as a biomarker for prostate cancer. We present a high-flow liquid chromatography–tandem mass spectrometry (LC-MS/MS) method for measuring serum ZAG concentrations by proteolytic cleavage of the protein and quantification of a unique peptide.Methods: We selected the ZAG tryptic peptide 147EIPAWVPEDPAAQITK162 as the intact protein for quantification and used a stable isotope-labeled synthetic peptide with this sequence as an internal standard. Standards using recombinant ZAG in bovine serum albumin, 50 g/L, and a pilot series of patient sera were denatured, reduced, alkylated, and digested with trypsin. The concentration of ZAG was calculated from a dose–response curve of the ratio of the relative abundance of the ZAG tryptic peptide to internal standard.Results: The limit of detection for ZAG in serum was 0.08 mg/L, and the limit of quantification was 0.32 mg/L with a linear dynamic range of 0.32 to 10.2 mg/L. Replicate digests from pooled sera run during a period of 3 consecutive days showed intraassay imprecision (CV) of 5.0% to 6.3% and interassay imprecision of 4.4% to 5.9%. Mean (SD) ZAG was higher in 25 men with prostate cancer [7.59 (2.45) mg/L] than in 20 men with nonmalignant prostate disease [6.21 (1.65) mg/L, P = 0.037] and 6 healthy men [3.65 (0.71) mg/L, P = 0.0007].Conclusions: This LC-MS/MS assay is reproducible and can be used to evaluate the clinical utility of ZAG as a cancer biomarker.
A secondary progressive clinical course is uncommon in neuromyelitis optica
Wingerchuk, Dean M. , Pittock, Sean J. , Lucchinetti, Claudia F. , Lennon, Vanda A. , Weinshenker, Brian G. , Pittock, S J , Weinshenker, Brian G

Mayo Clinic

Neurology | February 19, 2007 | Volume: 68 | Issue: 8 | Pages: 603-605

10.1212/01.wnl.0000254502.87233.9a | PMID 17310032 Get It

Effect of referral bias on assessing survival in ALS
Sorenson, Eric J. , Mandrekar, Jayawant N. , Stevens, J. Clarke, Crum, Brian A.

Mayo Clinic

Neurology | February 19, 2007 | Volume: 68 | Issue: 8 | Pages: 600-602

10.1212/01.wnl.0000254501.58158.e7 | PMID 17310031 Get It

World War II Short Course: A Personal View
Martin, David P. , Burkle, Christopher M. , McGlinch, Brian P., Warner, Mary E. , Sessler, Alan D., Bacon, Douglas R.

Mayo Clinic

Anesthesiology | February 19, 2007 | Volume: 106 | Issue: 3 | Pages: 639-639

10.1097/00000542-200703000-00042 Get It

Innovations and Challenges in Renal Cell Carcinoma: Summary Statement from the Second Cambridge Conference
Figlin, Robert A. , George, Daniel J. , Kaelin, William G. , Kwon, Eugene D., Libermann, Towia A. , Pantuck, Allan J., Rosen, Mark, Sosman, Jeffrey A. , Sukhatme, Vikas P. , Vieweg, Johannes, Wood, Christopher G. , Atkins, Michael B. , Ernstoff, Marc S. , Flaherty, Keith T. , Linehan, William Marston , McDermott, David F. , Ochoa, Augusto C. , Rini, Brian I. , King, Laura

Mayo Clinic

Clinical Cancer Research | January 25, 2007 | Volume: 13 | Issue: 2 | Pages: 667s-670s

10.1158/1078-0432.ccr-06-2231 | PMID 17255291 Get It

Abstract Innovations and Challenges in Renal Cancer, chaired by Michael B. Atkins, was held April 28 to 29, 2006 in Cambridge, Massachusetts. The conference brought together leading experts in the fields of cancer research, medical oncology, urology, immunology, radiology, and immunotherapy, with the goal of advancing the field of renal cancer treatment by critiquing new data from ongoing clinical trials and stimulating communication among those involved in basic and clinical research. The conference proceedings published in this educational supplement to Clinical Cancer Research are intended to provide timely information and recommendations on important aspects of renal cancer genetics and biology and advances in prognostic classification and treatment.
Databases in MS research: pitfalls and promises
Weinshenker, Brian G.

Mayo Clinic

Multiple Sclerosis Journal | January 18, 2007 | Volume: 5 | Issue: 4 | Pages: 206-211

10.1177/135245859900500402 | PMID 10467376 Get It

A database is an organized repository of data. Prospective collection of patient information in a database (`databasing') has been attempted by a few consortia of MS investigators over the past 10 years. This approach promises to facilitate epidemiologic research in MS and investigation of the natural history of the disease and how it might be altered by long-term treatments such as interferon beta. Databasing has some advantages over clinical trials in assessing new therapies, primarily because the focus is on long-term effectiveness in an entire population rather than short-term statistical significance in a highly selected population. The limitations of databasing and strategies to overcome these limitations are addressed.
Results at up to 20 years after ileal pouch–anal anastomosis for chronic ulcerative colitis
Hahnloser, Dieter , Pembérton, John H., Wolff, B. G., Larson, David R., Crownhart, Brian S., Dozois, Roger R., Hahnloser, Dieter

Mayo Clinic

British Journal of Surgery | January 16, 2007 | Volume: 94 | Issue: 3 | Pages: 333-340

10.1002/bjs.5464 | PMID 17225210 Get It

Abstract Background Ileal pouch–anal anastomosis (IPAA) is performed routinely for chronic ulcerative colitis. Methods Using data from a prospective database and annual standardized questionnaires, functional outcome, complications and quality of life (QoL) after IPAA were assessed. Results Some 1885 IPAA operations were performed for chronic ulcerative colitis over a 20-year period (mean follow-up 11 years). The mean age at the time of IPAA was 34·1 years, increasing from 31·2 years (1981–1985) to 36·3 years (1996–2000). The overall rate of pouch success at 5, 10, 15 and 20 years was 96·3, 93·3, 92·4 and 92·1 per cent respectively. Mean daytime stool frequency increased from 5·7 at 1 year to 6·4 at 20 years (P < 0·001), and also increased at night (from 1·5 to 2·0; P < 0·001). The incidence of frequent daytime faecal incontinence increased from 5 to 11 per cent during the day (P < 0·001) and from 12 to 21 per cent at night (P < 0·001). QoL remained unchanged and 92 per cent remained in the same employment. Seventy-six patients were eventually diagnosed with indeterminate colitis and 47 with Crohn's disease. Conclusion IPAA is a reliable surgical procedure for patients requiring proctocolectomy for chronic ulcerative colitis and indeterminate colitis. The clinical and functional outcomes are excellent and stable for 20 years after operation.
IBM Solves a Mixed-Integer Program to Optimize Its Semiconductor Supply Chain
Forrest, J. J. H., Milne, R. John , Denton, Brian T.

Mayo Clinic

Interfaces | December 22, 2006 | Volume: 36 | Issue: 5 | Pages: 386-399

10.1287/inte.1060.0238 Get It

IBM Systems and Technology Group uses operations research models and methods extensively for solving large-scale supply chain optimization (SCO) problems for planning its extended enterprise semiconductor supply chain. The large-scale nature of these problems necessitates the use of computationally efficient solution methods. However, the complexity of the models makes developing robust solution methods a challenge. We developed a mixed-integer programming (MIP) model and supporting heuristics for optimizing IBM’s semiconductor supply chain. We designed three heuristics, driven by practical applications, for capturing the discrete aspects of the MIP. We leverage the model structure to overcome computational hurdles resulting from the large-scale problem. IBM uses the model and method daily for operational and strategic planning decisions and has saved substantial costs.
Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10 211 cases and 11 905 controls from the International Lymphoma Epidemiology Consortium (InterLymph)
Wang, Sophia , Brennan, Paul , Holly, Elizabeth A., Sanjosé, Sílvia de, Cerhan, James R. , Spinelli, John J., Cocco, Pier Luigi, Mensah, Fiona , Nieters, Alexandra, Maso, Luigino Dal , Bracci, Paige M. , Costantini, Adele Seniori , Vineis, Paolo , Severson, Richard K., Roman, Eve , Weisenburger, Dennis D. , Franceschi, Silvia , Vecchia, Carlo La , Foretová, Lenka , Becker, Nikolaus, Staines, Anthony , Vornanen, Martine, Zheng, Tongzhang, Hartge, Patricia, Cocco, Pierluigi , Slager, Susan L. , Bernstein, Leslie , Boffetta, Paolo , Maynadié, Marc , Chiu, Brian C.‐H. , Zhang, Yawei , Cozen, Wendy , Davis, Scott , Cerhan, James R , Cocco, Pierluigi , Wang, Sophia S , Roman, Eve

Mayo Clinic

Blood | December 22, 2006 | Volume: 109 | Issue: 8 | Pages: 3479-3488

10.1182/blood-2006-06-031948 | PMID 17185468 Get It

AbstractA role for genetic susceptibility in non-Hodgkin lymphoma (NHL) is supported by the accumulating evidence of common genetic variations altering NHL risk. However, the pattern of NHL heritability remains poorly understood. We conducted a pooled analysis of 10 211 NHL cases and 11 905 controls from the International Lymphoma Epidemiology Consortium (InterLymph) to evaluate NHL risk among those with hematopoietic malignancies in first-degree relatives. Odds ratios (ORs) and 95% confidence intervals (CIs) of NHL and its subtypes were estimated from unconditional logistic regression models with adjustment for confounders. NHL risk was elevated for individuals who reported first-degree relatives with NHL (OR = 1.5; 95% CI = 1.2-1.9), Hodgkin lymphoma (OR = 1.6; 95% CI = 1.1-2.3), and leukemia (OR = 1.4; 95% CI = 1.2-2.7). Risk was highest among individuals who reported a brother with NHL (OR = 2.8; 95% CI = 1.6-4.8) and was consistent for all NHL subtypes evaluated. If a first-degree relative had Hodgkin lymphoma, NHL risk was highest if the relative was a parent (OR = 1.7; 95% CI = 1.0-2.9). If a first-degree relative had leukemia, NHL risk was highest among women who reported a sister with leukemia (OR = 3.0; 95% CI = 1.6-5.6). The pattern of NHL heritability appeared to be uniform across NHL subtypes, but risk patterns differed by specific hematopoietic malignancies and the sex of the relative, revealing critical clues to disease etiology.
Characterization of Multiple Multivesicular Body Sorting Determinants within Sna3: A Role for the Ubiquitin Ligase Rsp5
Oestreich, Andrea J., Aboian, Mariam , Lee, Jacqueline, Azmi, Ishara F. , Payne, Johanna A., Issaka, Rachel B. , Davies, Brian A., Katzmann, David J. , Aboian, Mariam S

Mayo Clinic

Molecular Biology of the Cell | December 21, 2006 | Volume: 18 | Issue: 2 | Pages: 707-720

10.1091/mbc.e06-08-0680 | PMID 17182849 Get It

A subset of proteins that transit the endosomal system are directed into the intralumenal vesicles of multivesicular bodies (MVBs). MVB formation is critical for a variety of cellular functions including receptor down-regulation, viral budding, antigen presentation, and the generation of lysosome-related organelles. Entry of transmembrane proteins into the intralumenal vesicles of a MVB is a highly regulated process that is positively modulated by covalent modification of cargoes with ubiquitin. To identify additional MVB sorting signals, we examined the previously described ubiquitination-independent MVB cargo Sna3. Although Sna3 ubiquitination is not essential, Sna3 MVB sorting is positively modulated by its ubiquitination. Examination of MVB sorting determinants within a form of Sna3 lacking all lysine residues identified two critical regions: an amino-terminal tyrosine-containing region and a carboxyl-terminal PPAY motif. This PPAY motif interacts with the WW domains of the ubiquitin ligase Rsp5, and mutations in either the WW or, surprisingly, the HECT domains of Rsp5 negatively impacted MVB targeting of lysine-minus Sna3. These data indicate that Rsp5 function is required for MVB targeting of Sna3 in a capacity beyond cargo ubiquitination. These results uncover a series of determinants impacting Sna3 MVB sorting, including unexpected roles for Rsp5.